I'll try to answer that.
Paragraph 21.03(1)(a) of the Patent Act, which has been struck out—but then effectively some sort of mechanism has been reinserted—is the process of amending schedule 1, the list of drugs for export. Paragraphs 21.03(1)(b) to (d) and subsection 21.03(2) of the Patent Act—that's basically the rest of section 21.03—have also been effectively removed. Those paragraphs and the subsection describe the processes and requirements for adding and removing a country from what were schedules 2 and 3 of the Patent Act, those lists of countries Mr. Sutherland-Brown was referring to that had various requirements for using the WTO waiver as per the international rules.
What clause 3 of Bill C-393 would do is, for these lists of countries, effectively modify that process so that only two factors—and there were many more in the Patent Act—could be taken into consideration for adding or removing an eligible country from the new schedule. This would significantly limit the ability to amend that list and take action.
I can give you a couple of examples of what clause 3 would eliminate, if that would help.